Disorders of the gut‐brain interaction among European people with obesity: Prevalence and burden of compatible symptoms
Symptoms compatible with DGBI are common among European people with obesity in the general population and are linked with certain demographic and disease-related factors. This should be acknowledged in the management of patients with obesity.
Authors
- Ami D. Sperber (ORCID: https://orcid.org/0000-0002-7634-3689)
- Olafur S. Palsson (ORCID: https://orcid.org/0000-0002-4480-3708)
- Jan F. Tack (ORCID: https://orcid.org/0000-0002-3206-6704)
- Shrikant I. Bangdiwala (ORCID: https://orcid.org/0000-0002-3111-0689)
- Jutta Keller (ORCID: https://orcid.org/0000-0002-5884-1115)
- Qasim Aziz (ORCID: https://orcid.org/0000-0002-2718-2065)
- Jean‐Marc Sabaté (ORCID: https://orcid.org/0000-0001-5591-3489)
- Chloé Melchior (ORCID: https://orcid.org/0000-0002-8146-1540)
- Jóhann P. Hreinsson (ORCID: https://orcid.org/0000-0002-0078-3063)
- Magnus Simrén (ORCID: https://orcid.org/0000-0002-1155-1313)
Institutions
- University of North Carolina at Chapel Hill (US)
- Ben-Gurion University of the Negev (IL)
- Inserm (FR)
- Queen Mary University of London (GB)
- Population Health Research Institute (CA)
- Université Sorbonne Paris Nord (FR)
- Hôpital Avicenne (FR)
- Hôpital Ambroise-Paré (FR)
- Israelitisches Krankenhaus (DE)
- Impact (CA)
- Université de Rouen Normandie (FR)
- University of Gothenburg (SE)
- McMaster University (CA)
- KU Leuven (BE)
Publication Details
- Journal
- United European Gastroenterology Journal
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1002/ueg2.12700
- Citations
- 3
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.43
Funders
- Shire
- Takeda Pharmaceutical Company
- Ironwood Pharmaceuticals, Incorporated
- Allergan